Advertisement

Journal of Endocrinological Investigation

, Volume 42, Issue 5, pp 549–555 | Cite as

Effects of metabolic abnormalities, hyperandrogenemia and clomiphene on liver function parameters among Chinese women with polycystic ovary syndrome: results from a randomized controlled trial

  • W.-Y. Cai
  • J.-S. Gao
  • X. Luo
  • H.-L. Ma
  • H. Ge
  • N. Liu
  • Q. Xia
  • Y. Wang
  • B.-W. Han
  • X.-K. WuEmail author
Original Article

Abstract

Purpose

To investigate the effects of metabolic abnormalities, hyperandrogenemia and ovulation induction by clomiphene/acupuncture on liver function parameters among women with polycystic ovary syndrome (PCOS).

Methods

This is a secondary analysis of a randomized controlled trial. All 1000 subjects were diagnosed as PCOS by modified Rotterdam criteria. Liver function parameters, metabolic panel and hormone profile were measured at baseline and after treatment. The relationship between liver parameters with metabolic, hormonal parameters and ovulation induction was examined.

Results

PCOS women with metabolic syndrome had higher liver enzyme levels but lower bilirubin and bile acid levels than without. PCOS women with hyperandrogenemia had higher liver enzyme, bilirubin levels than without. Correlation analyses showed that worsening of metabolic parameters was associated with higher liver enzyme levels but lower bilirubin and bile acid levels, while increased androgen levels were associated with higher liver enzyme, bilirubin and bile acid levels. Ovulation induction with clomiphene citrate could decrease bilirubin and bile acid levels, while acupuncture had no obvious effect on liver function.

Conclusions

Among PCOS women, metabolic abnormalities and hyperandrogenemia impaired different liver function parameters. Clomiphene could decrease the bilirubin and bile acid levels while acupuncture had no obvious effect on liver function.

Keywords

PCOS Liver function Metabolic syndrome Hyperandrogenemia Ovulation induction 

Notes

Acknowledgements

The content is solely the responsibility of the authors and does not necessarily represent the official views of the State Administration of Traditional Chinese Medicine of People’s Republic of China. The Steering Committee (SC) members included Xiao-Ke Wu, Jiang-Ping Liu, Tai-Xiang Wu, Ernest HY Ng, Elisabet Stener-Victorin and Heping Zhang, and Richard S Legro (Chair). The Data and Safety Monitoring Board (DSMB) members included Esther Eisenberg, Wei-Liang Weng, Su-Lun Sun, Wei Zou and Zi-Dan Chen, and Robert Rebar (Chair). Meizhuo Zhang in Yale, contributed to the randomization scheme and training of our study personnel. Jin-Ying Fu, Chang-Ling Zhu and Xiao-Hong Wang participated in the patient recruitment at local sites of Henan, Wenzhou and Xuzhou. Other personnel with administrative resource supports included Song-Jiang Liu, Gui-Yuan Wang, Yan-Qiu Du, Yang Xia, Shu-Lai Li, Ke-Qiu Zhang, and Jian-Hua Shen. Yan Li, Wen-Juan Shen, Wei Li and Jing Cong were involved in protocol preparation and blood sample management in Harbin office and core laboratory. We thank the Reproductive Medicine Network Steering Committee of the National Institutes of Health for sharing the protocol and case-report forms from the Pregnancy in Polycystic Ovary Syndrome II study.

Funding

National Public Welfare Projects for Chinese Medicine (201107005, 200807002), the National Key Discipline of Chinese Medicine in Gynecology during the year of 2009–2016, (JC200804), the Intervention for Polycystic Ovary Syndrome Based on Traditional Chinese Medicine Theory—‘Tian Gui Disorder’ (2011TD006), and the National Clinical Trial Base in Chinese Medicine Special Projects (JDZX2012036, 2015B009) during the year of 2009–2016 for the First Affiliated Hospital, Heilongjiang University of Chinese Medicine, as well as the Heilongjiang Province ‘Longjiang Scholar’ Program to Xiao-Ke Wu.

Compliance with ethical standards

Conflict of interest

All authors had no conflict of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370(9588):685–697.  https://doi.org/10.1016/s0140-6736(07)61345-2 CrossRefGoogle Scholar
  2. 2.
    Björndahl L, Giwercman ‎A, Tournaye H (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41–47CrossRefGoogle Scholar
  3. 3.
    Kelley CE, Brown AJ, Diehl AM, Setji TL (2014) Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 20(39):14172–14184.  https://doi.org/10.3748/wjg.v20.i39.14172 CrossRefGoogle Scholar
  4. 4.
    Schwimmer JB, Khorram O, Chiu V, Schwimmer WB (2005) Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 83(2):494–497.  https://doi.org/10.1016/j.fertnstert.2004.08.020 CrossRefGoogle Scholar
  5. 5.
    Rocha ALL, Faria LC, Guimaraes TCM, Moreira GV, Candido AL, Couto CA, Reis FM (2017) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Investig 40(12):1279–1288.  https://doi.org/10.1007/s40618-017-0708-9 CrossRefGoogle Scholar
  6. 6.
    Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33(6):981–1030.  https://doi.org/10.1210/er.2011-1034 CrossRefGoogle Scholar
  7. 7.
    Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R (2011) Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7(4):219–231.  https://doi.org/10.1038/nrendo.2010.217 CrossRefGoogle Scholar
  8. 8.
    Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C (2010) Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2(32):32–35.  https://doi.org/10.1126/scitranslmed.3001143 CrossRefGoogle Scholar
  9. 9.
    Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN (2010) Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 95(7):3332–3341.  https://doi.org/10.1210/jc.2009-2698 CrossRefGoogle Scholar
  10. 10.
    Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener-Victorin E, Fauser BC, Norman RJ, Teede H (2016) The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 22(6):687–708.  https://doi.org/10.1093/humupd/dmw025 CrossRefGoogle Scholar
  11. 11.
    Pastore LM, Williams CD, Jenkins J, Patrie JT (2011) True and sham acupuncture produced similar frequency of ovulation and improved LH to FSH ratios in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96(10):3143–3150.  https://doi.org/10.1210/jc.2011-1126 CrossRefGoogle Scholar
  12. 12.
    Bovey M, Lorenc A, Robinson N (2010) Extent of acupuncture practice for infertility in the United Kingdom: experiences and perceptions of the practitioners. Fertil Steril 94(7):2569–2573.  https://doi.org/10.1016/j.fertnstert.2010.03.072 CrossRefGoogle Scholar
  13. 13.
    Johansson J, Redman L, Veldhuis PP, Sazonova A, Labrie F, Holm G, Johannsson G, Stener-Victorin E (2013) Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab 304(9):E934–E943.  https://doi.org/10.1152/ajpendo.00039.2013 CrossRefGoogle Scholar
  14. 14.
    Smith CA, Armour M, Betts D (2014) Treatment of women’s reproductive health conditions by Australian and New Zealand acupuncturists. Complement Ther Med 22(4):710–718.  https://doi.org/10.1016/j.ctim.2014.06.001 CrossRefGoogle Scholar
  15. 15.
    Sui Y, Zhao HL, Wong VC, Brown N, Li XL, Kwan AK, Hui HL, Ziea ET, Chan JC (2012) A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obes Rev 13(5):409–430.  https://doi.org/10.1111/j.1467-789X.2011.00979.x CrossRefGoogle Scholar
  16. 16.
    Martinez B, Peplow PV (2016) Treatment of insulin resistance by acupuncture: a review of human and animal studies. Acupunct Med 34(4):310–319.  https://doi.org/10.1136/acupmed-2016-011074 CrossRefGoogle Scholar
  17. 17.
    Wu XK, Stener-Victorin E, Kuang HY, Ma HL, Gao JS, Xie LZ, Hou LH, Hu ZX, Shao XG, Ge J, Zhang JF, Xue HY, Xu XF, Liang RN, Ma HX, Yang HW, Li WL, Huang DM, Sun Y, Hao CF, Du SM, Yang ZW, Wang X, Yan Y, Chen XH, Fu P, Ding CF, Gao YQ, Zhou ZM, Wang CC, Wu TX, Liu JP, Ng EHY, Legro RS, Zhang H (2017) Effect of acupuncture and clomiphene in Chinese women with polycystic ovary syndrome: a randomized clinical trial. JAMA 317(24):2502–2514.  https://doi.org/10.1001/jama.2017.7217 CrossRefGoogle Scholar
  18. 18.
    Kuang H, Li Y, Wu X, Hou L, Wu T, Liu J, Ng EH, Stener-Victorin E, Legro RS, Zhang H (2013) Acupuncture and clomiphene citrate for live birth in polycystic ovary syndrome: study design of a randomized controlled trial. Evid Based Complement Altern Med (ECAM) 2013:527303.  https://doi.org/10.1155/2013/527303 Google Scholar
  19. 19.
    Targher G, Rossini M, Lonardo A (2016) Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine 51(2):211–221.  https://doi.org/10.1007/s12020-015-0640-8 CrossRefGoogle Scholar
  20. 20.
    Lee MJ, Jung CH, Kang YM, Hwang JY, Jang JE, Leem J, Park JY, Kim HK, Lee WJ (2014) Serum bilirubin as a predictor of incident metabolic syndrome: a 4-year retrospective longitudinal study of 6205 initially healthy Korean men. Diabetes Metab 40(4):305–309.  https://doi.org/10.1016/j.diabet.2014.04.006 CrossRefGoogle Scholar
  21. 21.
    Li XH, Lin HY, Guan LY, Peng H, Wen MM, Cao YQ, Jiang XY, Wang YB (2017) Direct bilirubin levels and risk of metabolic syndrome in healthy Chinese men. Biomed Res Int 2017:9621615.  https://doi.org/10.1155/2017/9621615 Google Scholar
  22. 22.
    Kawamoto R, Ninomiya D, Senzaki K, Kumagi T (2017) Alanine aminotransferase and total bilirubin are synergistically associated with metabolic syndrome among middle-aged and elderly Japanese women. Metab Syndr Relat Disord 15(8):407–415.  https://doi.org/10.1089/met.2017.0064 CrossRefGoogle Scholar
  23. 23.
    Lee HS, Park T (2017) Pathway-driven approaches of interaction between oxidative balance and genetic polymorphism on metabolic syndrome. Oxid Med Cell Longev 2017:6873197.  https://doi.org/10.1155/2017/6873197 Google Scholar
  24. 24.
    Hotamisligil GS (2003) Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27(Suppl 3):S53–S55.  https://doi.org/10.1038/sj.ijo.0802502 CrossRefGoogle Scholar
  25. 25.
    Gonzalez-Regueiro JA, Moreno-Castaneda L, Uribe M, Chavez-Tapia NC (2017) The role of bile acids in glucose metabolism and their relation with diabetes. Ann Hepatol 16(Suppl 1:s3–105):16–21.  https://doi.org/10.5604/01.3001.0010.5672 CrossRefGoogle Scholar
  26. 26.
    Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ (2009) Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 24(3):710–717.  https://doi.org/10.1093/humrep/den433 CrossRefGoogle Scholar
  27. 27.
    Singh C, Bishop P, Willson R (1996) Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: response to ursodeoxycholic acid treatment. Am J Gastroenterol 91(4):783–785Google Scholar
  28. 28.
    Okano A, Ohana M, Kusumi F (2014) Idiopathic cholestatic jaundice may be a paraneoplastic manifestation of underlying malignancy: a case of prostate cancer. Clin J Gastroenterol 7(3):278–282.  https://doi.org/10.1007/s12328-014-0484-4 CrossRefGoogle Scholar
  29. 29.
    Aubuchon M, Kunselman AR, Schlaff WD, Diamond MP, Coutifaris C, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Legro RS (2011) Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96(10):E1645–E1649.  https://doi.org/10.1210/jc.2011-1093 CrossRefGoogle Scholar
  30. 30.
    Beuers U, Kremer AE, Bolier R, Elferink RP (2014) Pruritus in cholestasis: facts and fiction. Hepatology 60(1):399–407.  https://doi.org/10.1002/hep.26909 CrossRefGoogle Scholar
  31. 31.
    Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C (2014) Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case–control study. Hepatology 59(4):1482–1491.  https://doi.org/10.1002/hep.26617 CrossRefGoogle Scholar
  32. 32.
    Glantz A, Marschall HU, Mattsson LA (2004) Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 40(2):467–474.  https://doi.org/10.1002/hep.20336 CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2018

Authors and Affiliations

  • W.-Y. Cai
    • 1
  • J.-S. Gao
    • 2
  • X. Luo
    • 1
  • H.-L. Ma
    • 2
  • H. Ge
    • 1
  • N. Liu
    • 1
  • Q. Xia
    • 1
  • Y. Wang
    • 2
  • B.-W. Han
    • 1
  • X.-K. Wu
    • 2
    Email author
  1. 1.Heilongjiang University of Chinese MedicineHarbinChina
  2. 2.Department of Obstetrics and Gynecology, First Affiliated HospitalHeilongjiang University of Chinese MedicineHarbinChina

Personalised recommendations